"10.1371_journal.pone.0046648","none","2012-10-15T00:00:00Z","Clarissa Pozzi; Katarzyna Wilk; Jean C Lee; Marina Gening; Nikolay Nifantiev; Gerald B Pier","Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia","Conceived and designed the experiments: CP GP JL. Performed the experiments: CP KW. Analyzed the data: CP KW GP. Contributed reagents/materials/analysis tools: NN MG. Wrote the paper: CP GP.","The authors have read the journal's policy and have the following conflicts: Gerald B. Pier has developed intellectual property that has been licensed for development of PNAG and PNAG-based vaccines as well as for monoclonal antibodies to the PNAG antigen and has received consulting income and licensing income from these arrangements. GBP also holds equity interest in Alopexx Pharmaceuticals LLC, which has licensed the rights to develop monoclonal antibody therapies for PNAG-expressing microbes and in Alopexx Vaccine LLC which has licensed rights to develop PNAG-based vaccines for animal and human use. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2012","10","Clarissa Pozzi","CP",6,TRUE,3,2,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
